Amgen Inc. is a multinational biotechnology and pharmaceutical company. It produces various drugs, including Neulasta, which prevents infections for patients undergoing cancer chemotherapy, Enbrel, a necrosis blocker for the treatment of autoimmune diseases. Focusing on molecular biology and biochemistry, Amgen aims at developing health care through recombinant DNA technology.
One Amgen Center Drive, Thousand Oaks, CA 91320-1799
CategoryBiotech & Pharmaceuticals
Amgen’s sustainability goals for 2027 – Where we want to be: 100% carbon neutral by 2027. Where we are: Amgen has noted a 30% reduction in water consumption since 2007. Where we want to be: An additional 40% reduction in water use by 2027. Where we are: Amgen has noted a 28% reduction in waste since 2007. We report on specific targets we’ve set for environmental conservation and improvements. We also measure our overall energy and carbon, water, waste, and sales. At Amgen, our employees bring innovation to life and make us who we are — a leader in serving patients. Our ability to deliver for patients is strengthened by attracting, retaining and promoting a diverse workforce of talented and engaged employees who believe in our mission and values. As the way people work post-pandemic continues to evolve, we are adapting how we recruit, develop and retain top talent from an array of fields and backgrounds. This includes providing employees opportunities to develop their skills to build meaningful careers. We are also taking a closer look at how we can better support the total health, safety and well-being of our staff. As of December 31, 2022, Amgen had approximately 25,200 staff members in over 50 countries, and we have had relatively low global turnover rates compared to available industry information. Following the COVID-19 pandemic, Amgen introduced a flexible workspace initiative that encourages eligible employees, working together with their manager, to choose the location best suited to their work. Employees who choose to work virtually part-or full-time can continue to come to an Amgen site for daily work and/or for activities that benefit from face- to-face collaboration, networking and recognition events.Amgen has a highly independent Board of Directors elected annually by a majority of our stockholders, with a lead independent director with robust responsibilities. Only independent Board members serve on key standing committees. Key standing committees of our Board include the Audit, Compensation and Management Development, Corporate Responsibility and Compliance, and the Governance and Nominating committees. Our Board of Directors is guided by our Amgen Board of Directors Corporate Governance Principles. Our Board has adopted an Amgen Board of Directors’ Code of Conduct (which applies to our Board) and a global Code of Conduct (which applies to our Board, all our employees and others conducting business on our behalf). Additionally, annual training on the global Code of Conduct is required of all our employees, and our Board participates in such training. We also have a code of ethics for senior financial officers. Amgen is a leading biotechnology company focused on developing and commercializing innovative therapies in areas like oncology, immunology, and bone health. The company’s success hinges on its strong drug pipeline, which includes both established treatments and novel therapies. Amgen has a history of solid financial performance, with substantial revenues and profitability.Operating in an ethical way with integrity and abiding by local, regional and national regulatory and legal standards that govern our industry is a non-negotiable part of how we do business. We expect the same of our partners and suppliers. Serving patients is a privilege, and ethics and compliance are critical to achieving our mission, realizing value for our stakeholders, and being the best place to work for our employees. We operate within a highly regulated and increasingly complex environment. Our Worldwide Compliance and Business Ethics organization is charged with navigating these requirements and anticipating emerging issues. We do this through our annual global risk assessment and by developing proactive plans to mitigate the risk of unethical business practices. We also periodically evaluate the effectiveness of our business ethics culture through third-party independent advisors who review and assess the maturity of our program and relevancy against latest guidance from regulators and industry best practices.